Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis

被引：0

作者：

Hansen, Michael K. ^{[1
]}

Connolly, Thomas M. ^{[1
]}

机构：

[1] Wyeth Res Discovery Translat Med, Collegeville, PA 19426 USA

来源：

CURRENT OPINION IN INVESTIGATIONAL DRUGS | 2008年 / 9卷 / 03期

关键词：

atherosclerosis; cardiovascular disease; dyslipidemia; farnesoid X receptor; liver X receptor; obesity; peroxisome proliferator-activated receptor;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Nuclear hormone receptors, including peroxisome proliferator-activated receptors (PPARs), liver X receptors (LXRs), and the farnesoid X receptor (FXR), are transcription factors involved in the regulation of essential metabolic functions, including glucose and lipid metabolism, reverse cholesterol transport, and the regulation of bile acids. This review summarizes new developments in the use of PPAR, LXR and FXR agonists for the treatment of obesity and cardiovascular diseases, including dyslipidemia and atherosclerosis. Currently available drugs and future areas of research for new therapies are also discussed.

引用

页码：247 / 255

页数：9

共 112 条

[11] Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE [J].

Bradley, Michelle N. ;

Hong, Cynthia ;

Chen, Mingyi ;

Joseph, Sean B. ;

Wilpitz, Damien C. ;

Wang, Xuping ;

Lusis, Aldons J. ;

Collins, Allan ;

Hseuh, Willa A. ;

Collins, Jon L. ;

Tangirala, Rajendra K. ;

Tontonoz, Peter .

JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (08) :2337-2346

[12] Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? [J].

Broeders, N ;

Knoop, C ;

Antoine, M ;

Tielemans, C ;

Abramowicz, D .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (12) :1993-1999

[13] Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart [J].

Burkart, Eileen M. ;

Sambandam, Nandakurnar ;

Han, Xianlin ;

Gross, Richard W. ;

Courtois, Michael ;

Gierasch, Carolyn M. ;

Shoghi, Kooresh ;

Welch, Michael J. ;

Kelly, Daniel P. .

JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (12) :3930-3939

[14] Farnesoid X receptor: A new player in glucose metabolism? [J].

Cariou, B ;

Duran-Sandoval, D ;

Kuipers, F ;

Staels, B .

ENDOCRINOLOGY, 2005, 146 (03) :981-983

[15] The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice [J].

Cariou, B ;

van Harmelen, K ;

Duran-Sandoval, D ;

van Dijk, TH ;

Grefhorst, A ;

Abdelkarim, M ;

Caron, S ;

Torpier, G ;

Fruchart, JC ;

Gonzalez, FJ ;

Kuipers, F ;

Staels, B .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (16) :11039-11049

[16] Nuclear receptors in macrophage biology: At the crossroads of lipid metabolism and inflammation [J].

Castrillo, A ;

Tontonoz, P .

ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 2004, 20 :455-480

[17] Nuclear receptors and lipid physiology: Opening the X-files [J].

Chawla, A ;

Repa, JJ ;

Evans, RM ;

Mangelsdorf, DJ .

SCIENCE, 2001, 294 (5548) :1866-1870

[18] Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice - Pleiotropic effects on CD36 expression and HDL [J].

Chen, Z ;

Ishibashi, S ;

Perrey, S ;

Osuga, J ;

Gotoda, T ;

Kitamine, T ;

Tamura, Y ;

Okazaki, H ;

Yahagi, N ;

Iizuka, Y ;

Shionoiri, F ;

Ohashi, K ;

Harada, K ;

Shimano, H ;

Nagai, R ;

Yamada, N .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (03) :372-377

[19]

Claudel T, 2002, J CLIN INVEST, V109, P961

[20] Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice [J].

Collins, AR ;

Meehan, WP ;

Kintscher, U ;

Jackson, S ;

Wakino, S ;

Noh, G ;

Palinski, W ;

Hsueh, WA ;

Law, RE .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (03) :365-371

← 1 2 3 4 5 6 7 8 9 10 →